Soru

Zorluk: OrtaGynecologic Infections

A 3434-year-old woman comes to the clinic for evaluation of severe vaginal itching and a thick, white vaginal discharge. She reports that this is her fourth such episode in the past 1010 months. For her prior episodes, she was treated with either an over-the-counter vaginal clotrimazole cream or a single dose of oral fluconazole, which completely resolved her symptoms each time. She has no history of diabetes mellitus, HIV, or immunosuppressant use. Her only medication is a combined oral contraceptive pill. Pelvic examination shows marked vulvar and vaginal erythema with adherent, cottage cheese-like discharge. Vaginal fluid analysis is performed:

TestResult
Vaginal pH4.04.0
Amine "whiff" testNegative
Saline wet mountNormal squamous epithelial cells, few leukocytes
KOH wet mountAbundant pseudohyphae and budding yeast

Which of the following is the most appropriate pharmacotherapy for this patient's current condition?

  1. A
    A single dose of oral fluconazole, repeated once if symptoms persist after 4848 hours
  2. B
    Intravaginal terconazole cream for 33 days
  3. Oral fluconazole every 7272 hours for 33 doses, followed by weekly oral fluconazole for 66 monthsCevap
  4. D
    Oral fluconazole and oral metronidazole for 77 days
  5. E
    Intramuscular ceftriaxone and a single dose of oral azithromycin

Cevap

Oral fluconazole every 72 hours for 3 doses, followed by weekly oral fluconazole for 6 months
This patient has Recurrent Vulvovaginal Candidiasis (RVVC), clinically defined as four or more symptomatic episodes of vulvovaginal candidiasis within a 12-month period. The diagnostic findings of a normal vaginal pH (4.04.0), a negative whiff test, and the presence of pseudohyphae and budding yeast on KOH preparation definitively confirm the fungal etiology. While uncomplicated vulvovaginal candidiasis is effectively treated with a short course of topical azoles or a single dose of oral fluconazole, this approach is insufficient for RVVC. The standard of care for RVVC requires a biphasic approach: induction therapy followed by maintenance suppressive therapy. The recommended induction regimen is oral fluconazole (150150 mg) every 7272 hours for a total of 33 doses (days 1, 4, and 7). This must be immediately followed by maintenance therapy with oral fluconazole once weekly for 66 months to reliably prevent relapse.

Adım Adım Çözüm

1
Analyze the patient's clinical history and presenting symptoms.
The patient presents with intense vaginal itching, thick white discharge, and reports ≥4\ge 4 episodes in the past 1212 months.
To identify the chronicity and defining characteristics of the current infectious episode.
2
Interpret the vaginal fluid analysis results.
Vaginal pH=4.0pH = 4.0 (normal), whiff test is negative, and KOH wet mount reveals pseudohyphae.
To definitively isolate the etiologic organism (Candida) and strictly exclude Bacterial Vaginosis or Trichomoniasis.
3
Synthesize findings to establish the specific diagnosis.
The diagnosis is Recurrent Vulvovaginal Candidiasis (RVVC).
RVVC is specifically defined by guidelines as 44 or more symptomatic episodes of vulvovaginal candidiasis within a 11-year timeframe.
4
Determine the appropriate, guideline-concordant treatment regimen.
Select oral fluconazole every 7272 hours for 33 doses (induction), followed by weekly fluconazole for 66 months (maintenance).
Standard short-course therapies are inadequate for RVVC; prolonged induction and suppressive maintenance are required to prevent relapse.

Anahtar Kavram

Recurrent vulvovaginal candidiasis (RVVC) is defined as 44 or more episodes in a 1212-month period and requires induction therapy (e.g., oral fluconazole every 7272 hours for 33 doses) followed by maintenance suppressive therapy (e.g., weekly oral fluconazole for 66 months).
Tahmini Süre:1m 15s
Bu soruyu puanla